Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Transcode Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
RNAZ
Nasdaq
8731
https://www.transcodetherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Transcode Therapeutics Inc
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
- Apr 15th, 2024 1:00 pm
TransCode Therapeutics Reports 2023 Results; Provides Business Update
- Apr 3rd, 2024 1:10 pm
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
- Mar 28th, 2024 12:30 pm
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
- Mar 11th, 2024 1:00 pm
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
- Mar 6th, 2024 9:15 pm
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
- Feb 20th, 2024 1:00 pm
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
- Jan 31st, 2024 9:05 pm
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
- Jan 29th, 2024 1:30 pm
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
- Jan 22nd, 2024 9:45 pm
TransCode (RNAZ) Down 50% on Issue of New Common Stock
- Jan 19th, 2024 6:09 pm
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
- Jan 18th, 2024 6:27 pm
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
- Jan 12th, 2024 9:05 pm
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
- Jan 11th, 2024 1:00 pm
TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives
- Jan 4th, 2024 1:05 pm
TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
- Dec 12th, 2023 1:30 pm
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
- Dec 5th, 2023 2:00 pm
TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
- Dec 4th, 2023 9:10 pm
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
- Nov 30th, 2023 7:53 pm
TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
- Nov 14th, 2023 9:30 pm
TransCode Therapeutics Withdraws Public Offering
- Oct 30th, 2023 8:33 pm
Scroll